**Reference:**

1. Cullen G, O'Toole A, Keegan D, Sheahon K, Hyland JM, O'Donoghue DP. Long-term clinical results of ileocecal resection for Crohn's disease. Inflammatory Bowel Diseases. 2007;13(11):1369-73.

2. Shivananda S, Hordijk ML, Pena AS, Mayberry JF. CROHNS-DISEASE - RISK OF RECURRENCE AND REOPERATION IN A DEFINED POPULATION. Gut. 1989;30(7):990-5.

3. Farmer RG, Whelan G, Fazio VW. LONG-TERM FOLLOW-UP OF PATIENTS WITH CROHNS-DISEASE - RELATIONSHIP BETWEEN THE CLINICAL-PATTERN AND PROGNOSIS. Gastroenterology. 1985;88(6):1818-25.

4. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Annals of Surgery. 2000;231(1):38-45.

5. Bemelman WA, Allez M. The surgical intervention: earlier or never? Best practice & research Clinical gastroenterology. 2014;28(3):497-503.

6. Heuman R, Boeryd B, Bolin T, Sjodahl R. THE INFLUENCE OF DISEASE AT THE MARGIN OF RESECTION ON THE OUTCOME OF CROHNS-DISEASE. British Journal of Surgery. 1983;70(9):519-21.

7. Graadal O, Nygaard K. Crohn disease. Long-term effects of surgical treatment. Tidsskrift for den Norske lageforening : tidsskrift for praktisk medicin, ny rakke. 1994;114(14):1603-5.

8. Kim NK, Senagore AJ, Luchtefeld MA, MacKeigan JM, Mazier WP, Belknap K. Long-term outcome after ileocecal resection for Crohn's disease. Gastroenterology. 1996;110(4):A1398-A.

9. Nordgren SR, Fasth SB, Oresland TO, Hulten LA. LONG-TERM FOLLOW-UP IN CROHNS-DISEASE. Scandinavian Journal of Gastroenterology. 1994;29(12):1122-8.

10. Weston LA, Roberts PL, Schoetz DJ, Coller JA, Murray JJ, Rusin LC. Ileocolic resection for acute presentation of Crohn's disease of the ileum. Diseases of the Colon & Rectum. 1996;39(8):841-6.

11. Wright EK, Kamm MA. Impact of drug therapy and surgery on quality of life in Crohn's disease: a systematic review. Inflamm Bowel Dis. 2015;21(5):1187-94.

12. Tromm A, Tromm CD, Huppe D, Schwegler U, Krieg M, May B. EVALUATION OF DIFFERENT LABORATORY TESTS AND ACTIVITY INDEXES REFLECTING THE INFLAMMATORY ACTIVITY OF CROHNS-DISEASE. Scandinavian Journal of Gastroenterology. 1992;27(9):774-8.

13. Vermeire S, Van Assche G, Rutgeerts P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nature Clinical Practice Gastroenterology & Hepatology. 2005;2(12):580-6.

14. Solem CA, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflammatory Bowel Diseases. 2005;11(8):707-12.

15. Garcia JC, Persky SE, Bonis PAL, Topazian M. Abscesses in Crohn's disease - Outcome of medical versus surgical treatment. Journal of Clinical Gastroenterology. 2001;32(5):409-12.

16. Gervais DA, Hahn PF, O'Neill MJ, Mueller PR. Percutaneous abscess drainage in Crohn disease: Technical success and short- and long-term outcomes during 14 years. Radiology. 2002;222(3):645-51.

17. Yamaguchi A, Matsui T, Sakurai T, Ueki T, Nakabayashi S, Yao T, et al. The clinical characteristics and outcome of intraabdominal abscess in Crohn's disease. Journal of Gastroenterology. 2004;39(5):441-8.

18. Bafford AC, Coakley B, Powers S, Greenwald D, Ha CY, Weintraub J, et al. The clinical impact of preoperative percutaneous drainage of abdominopelvic abscesses in patients with Crohn's disease. International Journal of Colorectal Disease. 2012;27(7):953-8.

19. Bermejo F, Garrido E, Chaparro M, Gordillo J, Manosa M, Algaba A, et al. Efficacy of different therapeutic options for spontaneous abdominal abscesses in Crohn's disease: Are antibiotics enough? Inflammatory Bowel Diseases. 2012;18(8):1509-14.

20. Mueller-Wille R, Iesalnieks I, Dornia C, Ott C, Jung EM, Friedrich C, et al. Influence of percutaneous abscess drainage on severe postoperative septic complications in patients with Crohn's disease. International Journal of Colorectal Disease. 2011;26(6):769-74.

21. Michelassi F, Upadhyay GA. Side-to-side isoperistaltic strictureplasty in the treatment of extensive Crohn's disease. Journal of Surgical Research. 2004;117(1):71-8.

22. Sampietro GM, Sartani A, Danelli P, Ghizzoni M, Sposito C, Maconi G, et al. Strictureplasty in the surgical treatment of complicated Crohn's disease. Annali italiani di chirurgia. 2003;74(6):659-63.

23. Tonelli F, Fedi M, Paroli GM, Fazi M. Indications and results of side-to-side isoperistaltic strictureplasty in Crohn's disease. Diseases of the Colon & Rectum. 2004;47(4):494-501.

24. Shatari T, Clark MA, Yamamoto T, Menon A, Keh C, Alexander-Williams J, et al. Long strictureplasty is as safe and effective as short strictureplasty in small-bowel Crohn's disease. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2004;6(6):438-41.

25. Poggioli G, Laureti S, Pierangeli F, Ugolini F. A new model of strictureplasty for multiple and long stenoses in Crohn's ileitis - Side-to-side diseased to disease-free anastomosis. Diseases of the Colon & Rectum. 2003;46(1):127-30.

26. Tichansky D, Cagir B, Yoo E, Marcus SM, Fry RD. Strictureplasty for Crohn's disease - Meta-analysis. Diseases of the Colon & Rectum. 2000;43(7):911-9.

27. Campbell L, Ambe R, Weaver J, Marcus SM, Cagir B. Comparison of Conventional and Nonconventional Strictureplasties in Crohn's Disease: A Systematic Review and Meta-Analysis. Diseases of the Colon & Rectum. 2012;55(6):714-26.

28. Reese GE, Purkayastha S, Tilney HS, von Roon A, Yamamoto T, Tekkis PP. Strictureplasty vs resection in small bowel Crohn's disease: an evaluation of short-term outcomes and recurrence. Colorectal Disease. 2007;9(8):686-94.

29. Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for crohn's disease: A systematic review and meta-analysis. Diseases of the Colon & Rectum. 2007;50(11):1968-86.

30. Fearnhead NS, Chowdhury R, Box B, George BD, Jewell DP, Mortensen NJM. Long-term follow-up of strictureplasty for Crohn's disease. British Journal of Surgery. 2006;93(4):475-82.

31. Fichera A, Lovadina S, Rubin M, Cimino F, Hurst RD, Michelassi F. Patterns and operative treatment of recurrent Crohn's disease: a prospective longitudinal study. Surgery. 2006;140(4):649-54.

32. Menon AM, Mirza AH, Moolla S, Morton DG. Adenocarcinoma of the small bowel arising from a previous strictureplasty for Crohn's disease: Report of a case. Diseases of the Colon & Rectum. 2007;50(2):257-9.

33. Hashemi M, Novell JR, Lewis AAM. Side-to-side stapled anastomosis may delay recurrence in Crohn's disease. Diseases of the Colon & Rectum. 1998;41(10):1293-6.

34. Scarpa M, Angriman I, Barollo M, Polese L, Ruffolo C, Bertin M, et al. Role of stapled and hand-sewn anastomoses in recurrence of Crohn's disease. Hepato-Gastroenterology. 2004;51(58):1053-7.

35. Yamamato T, Bain IM, Mylonakis E, Allan RN, Keighley MRB. Stapled functional end-to-end anastomosis versus sutured end-to-end anastomosis after ileocolonic resection in Crohn disease. Scandinavian Journal of Gastroenterology. 1999;34(7):708-13.

36. Tersigni R, Alessandroni L, Barreca M, Piovanello P, Prantera C. Does stapled functional end-to-end anastomosis affect recurrence of Crohn's disease after ileocolonic resection? Hepato-Gastroenterology. 2003;50(53):1422-5.

37. Scott NA, Sueling HM, Hughes LE. ANASTOMOTIC CONFIGURATION DOES NOT AFFECT RECURRENCE OF CROHNS-DISEASE AFTER ILEOCOLONIC RESECTION. International Journal of Colorectal Disease. 1995;10(2):67-9.

38. Ikeuchi H, Kusunoki M, Yamamura T. Long-term results of stapled and hand-sewn anastomoses in patients with Crohn's disease. Digestive Surgery. 2000;17(5):493-6.

39. Simillis C, Purkayastha S, Yamamoto T, Strong SA, Darzi AW, Tekkis PP. A meta-analysis comparing conventional end-to-end anastomosis vs. other anastomotic configurations after resection in Crohn's disease. Diseases of the Colon & Rectum. 2007;50(10):1674-87.

40. Choy PYG, Bissett IP, Docherty JG, Parry BR, Merrie A, Fitzgerald A. Stapled versus handsewn methods for ileocolic anastomoses. Cochrane Database of Systematic Reviews. 2011(9).

41. Benoist S, Panis Y, Beaufour A, Bouhnik Y, Matuchansky C, Valleur P. Laparoscopic ileocecal resection in Crohn's disease - A case-matched comparison with open resection. Surgical Endoscopy and Other Interventional Techniques. 2003;17(5):814-8.

42. Castiglione F, Diaferia M, Morace F, Labianca O, Meucci C, Cuomo A, et al. Risk factors for inflammatory bowel diseases according to the "hygiene hypothesis": A case-control, multi-centre, prospective study in Southern Italy. Journal of Crohns & Colitis. 2012;6(3):324-9.

43. Hansen TS, Jess T, Vind I, Elkjaer M, Nielsen MF, Gamborg M, et al. Environmental factors in inflammatory bowel disease: A case-control study based on a Danish inception cohort. Journal of Crohns & Colitis. 2011;5(6):577-84.

44. Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML. Population-based cases control study of inflammatory bowel disease risk factors. Journal of Gastroenterology and Hepatology. 2010;25(2):325-33.

45. Kaplan GG, Jackson T, Sands BE, Frisch M, Andersson RE, Korzenik J. The Risk of Developing Crohn's Disease After an Appendectomy: A Meta-Analysis. American Journal of Gastroenterology. 2008;103(11):2925-31.

46. Eshuis EJ, Slors JFM, Stokkers PCF, Sprangers MAG, Ubbink DT, Cuesta MA, et al. Long-term outcomes following laparoscopically assisted versus open ileocolic resection for Crohn's disease. British Journal of Surgery. 2010;97(4):563-8.

47. Stocchi L, Milsom JW, Fazio VW. Long-term outcomes of laparoscopic versus open ileocolic resection for Crohn's disease: Follow-up of a prospective randomized trial. Surgery. 2008;144(4):622-8.

48. Dasari BVM, McKay D, Gardiner K. Laparoscopic versus Open surgery for small bowel Crohn's disease. Cochrane Database of Systematic Reviews. 2011(1).

49. Tilney HS, Constantinides VA, Heriot AG, Nicolaou M, Athanasiou T, Ziprin P, et al. Comparison of laparoscopic and open ileocecal resection for Crohn's disease: a metaanalysis. Surgical Endoscopy and Other Interventional Techniques. 2006;20(7):1036-44.

50. Lesperance K, Martin MJ, Lehmann R, Brounts L, Steele SR. National Trends and Outcomes for the Surgical Therapy of Ileocolonic Crohn's Disease: A Population-Based Analysis of Laparoscopic vs. Open Approaches. Journal of Gastrointestinal Surgery. 2009;13(7):1251-9.

51. Milsom JW, Hammerhofer KA, Bohm B, Marcello P, Elson P, Fazio VW. Prospective, randomized trial comparing laparoscopic vs. conventional surgery for refractory ileocolic Crohn's disease. Diseases of the Colon & Rectum. 2001;44(1):1-8.

52. Eshuis EJ, Polle SW, Slors JF, Hommes DW, Sprangers MAG, Gouma DJ, et al. Long-term surgical recurrence, morbidity, quality of life, and body image of laparoscopic-assisted vs. open ileocolic resection for Crohn's disease: A comparative study. Diseases of the Colon & Rectum. 2008;51(6):858-67.

53. Lawes DA, Motson RW. Avoidance of laparotomy for recurrent disease is a long-term benefit of laparoscopic resection for Crohn's disease. British Journal of Surgery. 2006;93(5):607-8.

54. Alves A, Panis Y, Bouhnik Y, Marceau C, Rouach Y, Lavergne-Slove A, et al. Factors that predict conversion in 69 consecutive patients undergoing laparoscopic ileocecal resection for Crohn's disease: A prospective study. Diseases of the Colon & Rectum. 2005;48(12):2302-8.

55. Goyer P, Alves A, Bretagnol F, Bouhnik Y, Valleur P, Panis Y. Impact of Complex Crohn's Disease on the Outcome of Laparoscopic Ileocecal Resection: A Comparative Clinical Study in 124 Patients. Diseases of the Colon & Rectum. 2009;52(2):205-10.

56. Huang R, Valerian BT, Lee EC. Laparoscopic approach in patients with recurrent Crohn's disease. The American surgeon. 2012;78(5):595-9.

57. Tekkis PP, Purkayastha S, Lanitis S, Athanasiou T, Heriot AG, Orchard TR, et al. A comparison of segmental vs subtotal/total colectomy for colonic Crohn's disease: a meta-analysis. Colorectal Disease. 2006;8(2):82-90.

58. Yamamoto T, Keighley MRB. Proctocolectomy is associated with a higher complication rate but carries a lower recurrence rate than total colectomy and ileorectal anastomosis in Crohn colitis. Scandinavian Journal of Gastroenterology. 1999;34(12):1212-5.

59. Tonelli F, Paroli GM. Colorectal Crohn's disease: indications to surgical treatment. Annali italiani di chirurgia. 2003;74(6):665-72.

60. Longo WE, Ballantyne GH, Cahow E. TREATMENT OF CROHNS COLITIS - SEGMENTAL OR TOTAL COLECTOMY. Archives of Surgery. 1988;123(5):588-90.

61. Andersson P, Olaison G, Hallbook O, Sjodahl R. Segmental resection or subtotal colectomy in Crohn's colitis? Diseases of the Colon & Rectum. 2002;45(1):47-53.

62. Morini S, Hassan C, Lorenzetti R, Zullo A, Cerro P, Winn S, et al. Long-term outcome of endoscopic pneumatic dilatation in Crohn's disease. Digestive and Liver Disease. 2003;35(12):893-7.

63. Martel P, Betton PO, Gallot D, Malafosse M. Crohn's colitis: Experience with segmental resections; Results in a series of 84 patients. Journal of the American College of Surgeons. 2002;194(4):448-53.

64. Fichera A, McCormack R, Rubin VA, Hurst RD, Michelassi F. Long-term outcome of surgically treated Crohn's colitis: A prospective study. Diseases of the Colon & Rectum. 2005;48(5):963-9.

65. Thienpont C, D'Hoore A, Vermeire S, Demedts I, Bisschops R, Coremans G, et al. Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy. Gut. 2010;59(3):320-4.

66. Breysem Y, Janssens JF, Coremans G, Vantrappen G, Hendrickx G, Rutgeerts P. ENDOSCOPIC BALLOON DILATION OF COLONIC AND ILEOCOLONIC CROHNS STRICTURES - LONG-TERM RESULTS. Gastrointestinal Endoscopy. 1992;38(2):142-7.

67. Thomas-Gibson S, Brooker JC, Hayward CMM, Shah SG, Williams CB, Saunders BP. Colonoscopic balloon dilation of Crohn's strictures: a review of long-term outcomes. European Journal of Gastroenterology & Hepatology. 2003;15(5):485-8.

68. Krauss E, Agaimy A, Gottfried A, Maiss J, Weidinger T, Albrecht H, et al. Long term follow up of through-the-scope balloon dilation as compared to strictureplasty and bowel resection of intestinal strictures in crohn's disease. International journal of clinical and experimental pathology. 2014;7(11):7419-31.

69. Hassan C, Zullo A, De Francesco V, Ierardi E, Giustini M, Pitidis A, et al. Systematic review: endoscopic dilatation in Crohn's disease. Alimentary Pharmacology & Therapeutics. 2007;26(11-12):1457-64.

70. Sagar PM, Dozois RR, Wolff BG. Long-term results of ileal pouch-anal anastomosis in patients with Crohn's disease. Diseases of the Colon & Rectum. 1996;39(8):893-8.

71. Hyman NH, Fazio VW, Tuckson WB, Lavery IC. CONSEQUENCES OF ILEAL POUCH-ANAL ANASTOMOSIS FOR CROHNS COLITIS. Diseases of the Colon & Rectum. 1991;34(8):653-7.

72. Mylonakis E, Allan RN, Keighley MRB. How does pouch construction for a final diagnosis of Crohn's disease compare with ileoproctostomy for established Crohn's proctocolitis? Diseases of the Colon & Rectum. 2001;44(8):1137-42.

73. de Oca J, Sanchez-Santos R, Rague JM, Biondo S, Pares D, Osorio A, et al. Long-term results of heal pouch-anal anastomosis in Crohn's disease. Inflammatory Bowel Diseases. 2003;9(3):171-5.

74. Brown CJ, MacLean AR, Cohen Z, MacRae HM, O'Connor BI, McLeod RS. Crohn's disease and indeterminate colitis and the ileal pouch-anal anastomosis: Outcomes and patterns of failure. Diseases of the Colon & Rectum. 2005;48(8):1542-9.

75. Fazio VW, Kiran RP, Remzi FH, Coffey JC, Heneghan HM, Kirat HT, et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg. 2013;257(4):679-85.

76. Prudhomme M, Dehni N, Dozois RR, Tiret E, Parc R. Causes and outcomes of pouch excision after restorative proctocolectomy. British Journal of Surgery. 2006;93(1):82-6.

77. Sagar PM, Pemberton JH. Intraoperative, postoperative and reoperative problems with ileoanal pouches. British Journal of Surgery. 2012;99(4):454-68.

78. Spinelli A, Allocca M, Jovani M, Danese S. Review article: optimal preparation for surgery in Crohn's disease. Alimentary pharmacology & therapeutics. 2014;40(9):1009-22.

79. Chang MI, Cohen BL, Greenstein AJ. A review of the impact of biologics on surgical complications in Crohn's disease. Inflamm Bowel Dis. 2015;21(6):1472-7.

80. Serradori T, Germain A, Scherrer ML, Ayav C, Perez M, Romain B, et al. The effect of immune therapy on surgical site infection following Crohn's Disease resection. British Journal of Surgery. 2013;100(8):1089-93.

81. Syed A, Cross RK, Flasar MH. Anti-Tumor Necrosis Factor Therapy Is Associated With Infections after Abdominal Surgery in Crohn's Disease Patients. American Journal of Gastroenterology. 2013;108(4):583-93.

82. Billioud V, Ford AC, Del Tedesco E, Colombel J-F, Roblin X, Peyrin-Biroulet L. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis. Journal of Crohns & Colitis. 2013;7(11):853-67.

83. El-Hussuna A, Theede K, Olaison G. Increased risk of post-operative complications in patients with Crohn's disease treated with anti-tumour necrosis factor alpha agents - a systematic review. Danish medical journal. 2014;61(12):A4975.

84. Rizzo G, Armuzzi A, Pugliese D, Verbo A, Papa A, Mattana C, et al. Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. International Journal of Colorectal Disease. 2011;26(11):1435-44.

85. Rosenfeld G, Qian H, Bressler B. The risks of post-operative complications following pre-operative infliximab therapy for Crohn's disease in patients undergoing abdominal surgery: A systematic review and meta-analysis. Journal of Crohns & Colitis. 2013;7(11):868-77.

86. Kopylov U, Ben-Horin S, Zmora O, Eliakim R, Katz LH. Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis. Inflammatory Bowel Diseases. 2012;18(12):2404-13.

87. Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003;125(2):320-7.

88. Tay GS, Binion DG, Eastwood D, Otterson MF. Multivariate analysis suggests improved perioperative outcome in Crohn's disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery. 2003;134(4):565-72.

89. Myrelid P, Andersson P, Sjödahl R, Olaison G. Immunosuppression for Crohn´s disease is associated with increased frequency of anastomotic complications. Colorectal Disease. 2004;6:26.

90. Kunitake H, Hodin R, Shellito P, Sands B, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn s disease and ulcerative colitis is not associated with an increased rate of postoperative complications. Journal of Gastrointestinal Surgery. 2008;12(10):1730-6.

91. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990;99(4):956-63.

92. Vuitton L, Koch S, Peyrin-Biroulet L. Preventing postoperative recurrence in Crohn's disease: what does the futurehold? Drugs. 2013;73(16):1749-59.

93. Regueiro M, Kip K, Schraut W, Baidoo L, Sepulveda A, Pesci M, et al. Crohn’s disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Disease. 2011;17(1):118-26.

94. Ananthakrishnan AN. Surgery for Crohn's disease: look harder, act faster. Lancet. 2015;385(9976):1370-1.

95. De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, et al. Crohn's disease management after intestinal resection: a randomised trial. Lancet. 2015;385(9976):1406-17.

96. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn's disease. British Journal of Surgery. 2000;87(12):1697-701.

97. Ramadas AV, Gunesh S, Thomas GAO, Williams GT, Hawthorne AB. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut. 2010;59(9):1200-6.

98. Solberg IC, Vatn MH, Hoie O, Stray N, Sauar J, Jahnsen J, et al. Clinical course in Crohn's disease: Results of a Norwegian population-based ten-year follow-up study. Clinical Gastroenterology and Hepatology. 2007;5(12):1430-8.

99. Lazarev M, Huang C, Bitton A, Cho J, Duerr R, McGovern D, et al. Relationship between proximal Crohn's disease location and disease behavior and surgery: a cross-sectional study of the IBD Genetics Consortium. Am J Gastroenterology. 2013;108(1):106-12.

100. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV, Jr. Surgery in a Population-Based Cohort of Crohn's Disease From Olmsted County, Minnesota (1970-2004). American Journal of Gastroenterology. 2012;107(11):1693-701.

101. Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard M-A. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut. 2011;60(7):930-6.

102. Lakatos PL, Golovics PA, David G, Pandur T, Erdelyi Z, Horvath A, et al. Has There Been a Change in the Natural History of Crohn's Disease? Surgical Rates and Medical Management in a Population-Based Inception Cohort from Western Hungary Between 1977-2009. American Journal of Gastroenterology. 2012;107(4):579-88.

103. Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP. The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. International Journal of Colorectal Disease. 2008;23(12):1213-21.

104. Jones GR, Kennedy NA, Lees CW, Arnott ID, Satsangi J. Systematic review: The use of thiopurines or anti-TNF in post-operative Crohn's disease maintenance--progress and prospects. Alimentary pharmacology & therapeutics. 2014;39(11):1253-65.

105. McLeod RS, Wolff BG, Ross S, Parkes R, McKenzie M, Investigators CT. Recurrence of Crohn's Disease After Ileocolic Resection Is Not Affected by Anastomotic Type: Results of a Multicenter, Randomized, Controlled Trial. Diseases of the Colon & Rectum. 2009;52(5):919-27.

106. Ng SC, Lied GA, Arebi N, Phillips RK, Kamm MA. Clinical and surgical recurrence of Crohn's disease after ileocolonic resection in a specialist unit. European Journal of Gastroenterology & Hepatology. 2009;21(5):551-7.

107. Simillis C, Yamamoto T, Reese GE, Umegae S, Matsumoto K, Darzi AW, et al. A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating Versus nonperforating Crohn's disease. American Journal of Gastroenterology. 2008;103(1):196-205.

108. Greenstein AJ, Lachman P, Sachar DB, Springhorn J, Heimann T, Janowitz HD, et al. PERFORATING AND NON-PERFORATING INDICATIONS FOR REPEATED OPERATIONS IN CROHNS-DISEASE - EVIDENCE FOR 2 CLINICAL FORMS. Gut. 1988;29(5):588-92.

109. Hofer B, Bottger T, Hernandez-Richter T, Seifert JK, Junginger T. The impact of clinical types of disease manifestation on the risk of early postoperative recurrence in Crohn's disease. Hepato-Gastroenterology. 2001;48(37):152-5.

110. Parente F, Sampietro GM, Molteni M, Greco S, Anderloni A, Sposito C, et al. Behaviour of the bowel wall during the first year after surgery is a strong predictor of symptomatic recurrence of Crohn's disease: a prospective study. Alimentary pharmacology & therapeutics. 2004;20(9):959-68.

111. Simillis C, Jacovides M, Reese GE, Yamamoto T, Tekkis PP. Meta-analysis of the Role of Granulomas in the Recurrence of Crohn Disease. Diseases of the Colon & Rectum. 2010;53(2):177-85.

112. Ferrante M, De Hertogh G, Hlavaty T, D'Haens G, Penninckv F, D'Hoore A, et al. The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence. Gastroenterology. 2006;130(6):1595-606.

113. Sokol H, Polin V, Lavergne-Slove A, Panis Y, Treton X, Dray X, et al. Plexitis as a predictive factor of early postoperative clinical recurrence in Crohn's disease. Gut. 2009;58(9):1218-25.

114. Bressenot A, Peyrin-Biroulet L. Histologic features predicting postoperative Crohn's disease recurrence. Inflamm Bowel Dis. 2015;21(2):468-75.

115. Dedombal FT, Burton I, Goligher JC. RECURRENCE OF CROHNS DISEASE AFTER PRIMARY EXCISIONAL SURGERY. Gut. 1971;12(7):519-&.

116. Wettergren A, Christiansen J. RISK OF RECURRENCE AND REOPERATION AFTER RESECTION FOR ILEOCOLIC CROHNS-DISEASE. Scandinavian Journal of Gastroenterology. 1991;26(12):1319-22.

117. Lennardj.Je, Stalder GA. PROGNOSIS AFTER RESECTION OF CHRONIC REGIONAL ILEITIS. Gut. 1967;8(4):332-&.

118. Anseline PF, Wlodarczyk J, Murugasu A. Presence of granulomas is associated with recurrence after surgery for Crohn's disease: Experience of a surgical unit. British Journal of Surgery. 1997;84(1):78-82.

119. Softley A, Myren J, Clamp SE, Bouchier IA, Watkinson G, de Dombal FT. Factors affecting recurrence after surgery for Crohn's disease. Scandinavian journal of gastroenterology Supplement. 1988;144:31-4.

120. Scarpa M, Angriman I, Barollo M, Polese L, Ruffolo C, Bertin M, et al. Risk factors for recurrence of stenosis in Crohn's disease. Acta bio-medica : Atenei Parmensis. 2003;74 Suppl 2:80-3.

121. Poggioli G, Laureti S, Selleri S, Brignola C, Grazi GL, Stocchi L, et al. Factors affecting recurrence in Crohn's disease - Results of a prospective audit. International Journal of Colorectal Disease. 1996;11(6):294-8.

122. Botti F, Carrara A, Antonelli B, Quadri F, Maino M, Cesana B, et al. The minimal bowel resection in Crohn's disease: analysis of prognostic factors on the surgical recurrence. Annali italiani di chirurgia. 2003;74(6):627-33.

123. Fazio VW, Marchetti F, Church JM, Goldblum JR, Lavery IC, Hull TL, et al. Effect of resection margins on the recurrence of Crohn's disease in the small bowel - A randomized controlled trial. Annals of Surgery. 1996;224(4):563-71.

124. Fazio V, Marchetti F. Crohn's disease and resection margins: bigger is not better. Adv Surg. 1999;32:135-68.

125. Hildebrandt U, Kessler K, Plusczyk T, Pistorius G, Vollmar B, Menger MD. Comparison of surgical stress between laparoscopic and open colonic resections. Surgical Endoscopy and Other Interventional Techniques. 2003;17(2):242-6.

126. Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G. NATURAL-HISTORY OF RECURRENT CROHNS-DISEASE AT THE ILEOCOLONIC ANASTOMOSIS AFTER CURATIVE SURGERY. Gut. 1984;25(6):665-72.

127. Whelan G, Farmer RG, Fazio VW, Goormastic M. RECURRENCE AFTER SURGERY IN CROHNS-DISEASE - RELATIONSHIP TO LOCATION OF DISEASE (CLINICAL-PATTERN) AND SURGICAL INDICATION. Gastroenterology. 1985;88(6):1826-33.

128. Tytgat GNJ, Mulder CJJ, Brummelkamp WH. ENDOSCOPIC LESIONS IN CROHNS-DISEASE EARLY AFTER ILEOCECAL RESECTION. Endoscopy. 1988;20(5):260-2.

129. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. PREDICTABILITY OF THE POSTOPERATIVE COURSE OF CROHNS-DISEASE. Gastroenterology. 1990;99(4):956-63.

130. Olaison G, Smedh K, Sjodahl R. NATURAL COURSE OF CROHNS-DISEASE AFTER ILEOCOLIC RESECTION - ENDOSCOPICALLY VISUALIZED ILEAL ULCERS PRECEEDING SYMPTOMS. Gut. 1992;33(3):331-5.

131. Caprilli R, Andreoli A, Capurso L, Corrao G, Dalbasio G, Gioieni A, et al. ORAL MESALAZINE (5-AMINOSALICYLIC ACID - ASACOL) FOR THE PREVENTION OF POSTOPERATIVE RECURRENCE OF CROHNS-DISEASE. Alimentary pharmacology & therapeutics. 1994;8(1):35-43.

132. Scarpa M, D'Inca R, Basso D, Ruffolo C, Polese L, Bertin E, et al. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease. Diseases of the Colon & Rectum. 2007;50(6):861-9.

133. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, et al. Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI. American Journal of Gastroenterology. 2010;105(1):162-9.

134. Schoepfer AM, Lewis JD. Serial fecal calprotectin measurements to detect endoscopic recurrence in postoperative Crohn's disease: is colonoscopic surveillance no longer needed? Gastroenterology. 2015;148(5):889-92.

135. Boschetti G, Laidet M, Moussata D, Stefanescu C, Roblin X, Phelip G, et al. Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's Disease. The American journal of gastroenterology. 2015.

136. Yamamoto T. The clinical value of faecal calprotectin and lactoferrin measurement in postoperative Crohn's disease. United European gastroenterology journal. 2015;3(1):5-10.

137. Yamamoto T, Shimoyama T, Bamba T, Matsumoto K. Consecutive Monitoring of Fecal Calprotectin and Lactoferrin for the Early Diagnosis and Prediction of Pouchitis after Restorative Proctocolectomy for Ulcerative Colitis. The American journal of gastroenterology. 2015.

138. Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology. 2015;148(5):938-47 e1.

139. Qiu Y, Mao R, Chen BL, He Y, Zeng ZR, Xue L, et al. Fecal calprotectin for evaluating postoperative recurrence of Crohn's disease: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2015;21(2):315-22.

140. Calabrese E, Petruzziello C, Onali S, Condino G, Zorzi F, Pallone F, et al. Severity of Postoperative Recurrence in Crohn's Disease: Correlation Between Endoscopic and Sonographic Findings. Inflammatory Bowel Diseases. 2009;15(11):1635-42.

141. Rispo A, Bucci L, Pesce G, Sabbatini F, de Palma GD, Grassia R, et al. Bowel sonography for the diagnosis and grading of postsurgical recurrence of Crohn's disease. Inflammatory Bowel Diseases. 2006;12(6):486-90.

142. Castiglione F, Bucci L, Pesce G, De Palma GD, Camera L, Cipolletta F, et al. Oral contrast-enhanced sonography for the diagnosis and grading of postsurgical recurrence of Crohn's disease. Inflammatory Bowel Diseases. 2008;14(9):1240-5.

143. Maria Paredes J, Ripolles T, Cortes X, Dolores Reyes M, Lopez A, Jesus Martinez M, et al. Non-invasive diagnosis and grading of postsurgical endoscopic recurrence in Crohn's disease Usefulness of abdominal ultrasonography and Tc-99m-hexamethylpropylene amineoxime-labelled leucocyte scintigraphy. Journal of Crohns & Colitis. 2010;4(5):537-45.

144. Soyer P, Boudiaf M, Sirol M, Dray X, Aout M, Duchat F, et al. Suspected Anastomotic Recurrence of Crohn Disease after Ileocolic Resection: Evaluation with CT Enteroclysis. Radiology. 2010;254(3):755-64.

145. Paparo F, Revelli M, Puppo C, Bacigalupo L, Garello I, Garlaschi A, et al. Crohn's disease recurrence in patients with ileocolic anastomosis: Value of computed tomography enterography with water enema. European Journal of Radiology. 2013;82(9):E434-E40.

146. Sailer J, Peloschek P, Reinisch W, Vogelsang H, Turetschek K, Schima W. Anastomotic recurrence of Crohn's disease after ileocolic resection: comparison of MR enteroclysis with endoscopy. European Radiology. 2008;18(11):2512-21.

147. Eliakim R. Video capsule endoscopy of the small bowel. Current Opinion in Gastroenterology. 2013;29(2):133-9.

148. Timmer A, Sutherland LR, Martin F, Canadian Mesalamine Remission Crohn's Dis S. Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. Gastroenterology. 1998;114(6):1143-50.

149. Brignola C, Cottone M, Pera A, Ardizzone S, Scribano ML, Defranchis R, et al. MESALAMINE IN THE PREVENTION OF ENDOSCOPIC RECURRENCE AFTER INTESTINAL RESECTION FOR CROHNS-DISEASE. Gastroenterology. 1995;108(2):345-9.

150. Florent C, Cortot A, Quandale P, Sahmoud T, Modigliani R, Sarfaty E, et al. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. European Journal of Gastroenterology & Hepatology. 1996;8(3):229-33.

151. Lochs H, Mayer M, Fleig WE, Mortensen PB, Bauer P, Genser D, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's disease Study VI. Gastroenterology. 2000;118(2):264-73.

152. Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: A 2-year trial. Gastroenterology. 2004;127(3):723-9.

153. McLeod RS, Wolff BG, Steinhart AH, Carryer PW, Orourke K, Andrews DF, et al. PROPHYLACTIC MESALAMINE TREATMENT DECREASES POSTOPERATIVE RECURRENCE OF CROHNS-DISEASE. Gastroenterology. 1995;109(2):404-13.

154. Caprilli R, Cottone M, Tonelli F, Sturniolo G, Castiglione F, Annese V, et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. Alimentary pharmacology & therapeutics. 2003;17(4):517-23.

155. Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database of Systematic Reviews. 2009(4).

156. Ewe K, Herfarth C, Malchow H, Jesdinsky HJ. POSTOPERATIVE RECURRENCE OF CROHNS-DISEASE IN RELATION TO RADICALITY OF OPERATION AND SULFASALAZINE PROPHYLAXIS - A MULTICENTER TRIAL. Digestion. 1989;42(4):224-32.

157. Hellers G, Cortot A, Jewell D, Leijonmarck CE, Lofberg R, Malchow H, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. Gastroenterology. 1999;116(2):294-300.

158. Ewe K, Bottger T, Buhr HJ, Ecker KW, Otto HF, German Budesonide Study G. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. European Journal of Gastroenterology & Hepatology. 1999;11(3):277-82.

159. van Loo ES, Dijkstra G, Ploeg RJ, Nieuwenhuijs VB. Prevention of postoperative recurrence of Crohn's disease. Journal of Crohns & Colitis. 2012;6(6):637-46.

160. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al. CONTROLLED TRIAL OF METRONIDAZOLE TREATMENT FOR PREVENTION OF CROHNS RECURRENCE AFTER ILEAL RESECTION. Gastroenterology. 1995;108(6):1617-21.

161. Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, Noman M, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: A randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005;128(4):856-61.

162. Herfarth HH, Katz JA, Hanauer SB, Sandborn WJ, Loftus EV, Jr., Sands BE, et al. Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflammatory Bowel Diseases. 2013;19(5):1073-9.

163. Ardizzone S, Maconi G, Sampietro GM, Russo A, Radice E, Colombo E, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology. 2004;127(3):730-40.

164. Herfarth H, Tjaden C, Lukas M, Obermeier F, Dilger K, Mueller R, et al. Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn's disease. Gut. 2006;55(10):1525-6.

165. D'Haens GR, Vermeire S, Van Assche G, Noman M, Aerden I, Van Olmew G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: A controlled randomized trial. Gastroenterology. 2008;135(4):1123-9.

166. Nos P, Hinojosa J, Aguilera V, Moles JR, Pastor M, Ponce J, et al. Azathioprine and 5-ASA in the prevention of postoperative recurrence of Crohn's disease. Gastroenterologia y hepatologia. 2000;23(8):374-8.

167. Reinisch W, Angelberger S, Petritsch W, Shonova O, Lukas M, Bar-Meir S, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut. 2010;59(6):752-9.

168. Peyrin-Biroulet L, Deltenre P, Ardizzone S, D'Haens G, Hanauer SB, Herfarth H, et al. Azathioprine and 6-Mercaptopurine for the Prevention of Postoperative Recurrence in Crohn's Disease: A Meta-Analysis. American Journal of Gastroenterology. 2009;104(8):2089-96.

169. Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, et al. Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection. Gastroenterology. 2009;136(2):441-50.

170. Regueiro M, Baidoo L, Kip KE, Swoger JM, Binion DG, Hashash JG, et al. Infliximab Maintenance Beyond One Year Prevents Postoperative Crohn's Disease Recurrence: Long-Term Follow-up From the Randomized Controlled Pilot Study. Gastroenterology. 2013;144(5):S173-S.

171. Yoshida K, Fukunaga K, Ikeuchi H, Kamikozuru K, Hida N, Ohda Y, et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis. 2012;18(9):1617-23.

172. Yoshida K, Fukunaga K, Ikeuchi H, Kamikozuru K, Hida N, Ohda Y, et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: A 3-year prospective randomized open trial. Inflammatory Bowel Diseases. 2012;18(9):1617-23.

173. Sorrentino D, Terrosu G, Avellini C, Maiero S. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Archives of Internal Medicine. 2007;167(16):1804-7.

174. Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D. Low-Dose Maintenance Therapy With Infliximab Prevents Postsurgical Recurrence of Crohn's Disease. Clinical Gastroenterology and Hepatology. 2010;8(7):591-9.

175. Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, et al. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology. 2016;150(7):1568-78.

176. Aguas M, Bastida G, Cerrillo E, Beltran B, Iborra M, Sanchez-Montes C, et al. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients. World Journal of Gastroenterology. 2012;18(32):4391-8.

177. Papamichael K, Archavlis E, Lariou C, Mantzaris GJ. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: A prospective, two-year, single center, pilot study. Journal of Crohns & Colitis. 2012;6(9):924-31.

178. Savarino E, Bodini G, Dulbecco P, Assandri L, Bruzzone L, Mazza F, et al. Adalimumab Is More Effective Than Azathioprine and Mesalamine at Preventing Postoperative Recurrence of Crohn's Disease: A Randomized Controlled Trial. American Journal of Gastroenterology. 2013;108(11):1731-42.

179. De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, et al. Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis. Alimentary pharmacology & therapeutics. 2015;42(7):867-79.

180. Singh S, Garg SK, Pardi DS, Wang Z, Murad MH, Loftus EV, Jr. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis. Gastroenterology. 2015;148(1):64-76 e2; quiz e14.

181. Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine F, et al. Multicenter randomized-control led clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflammatory Bowel Diseases. 2007;13(2):135-42.

182. Marteau P, Lemann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006;55(6):842-7.

183. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002;51(3):405-9.

184. Chermesh I, Tamir A, Reshef R, Chowers Y, Suissa A, Katz D, et al. Failure of synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Digestive Diseases and Sciences. 2007;52(2):385-9.

185. Madsen K, Backer JL, Leddin D, Dieleman LA, Bitton A, Feagan B, et al. A randomized controlled trial of VSL#3 for the prevention of endoscopic recurrence following surgery for Crohn's disease. Gastroenterology. 2008;134(4):A361-A.

186. Fedorak RN, Feagan BG, Hotte N, Leddin D, Dieleman LA, Petrunia DM, et al. The Probiotic VSL#3 Has Anti-inflammatory Effects and Could Reduce Endoscopic Recurrence After Surgery for Crohn's Disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2015;13(5):928-35 e2.

187. Colombel JF, Rutgeerts P, Malchow H, Jacyna M, Nielsen OH, Rask-Madsen J, et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut. 2001;49(1):42-6.

188. Gecse KB, Bemelman W, Kamm MA, Stoker J, Khanna R, Ng SC, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut. 2014;63(9):1381-92.

189. Ong EM, Ghazi LJ, Schwartz DA, Mortele KJ. Guidelines for imaging of Crohn's perianal fistulizing disease. Inflamm Bowel Dis. 2015;21(4):731-6.

190. Schwartz DA, Ghazi LJ, Regueiro M, Fichera A, Zoccali M, Ong EM, et al. Guidelines for the multidisciplinary management of Crohn's perianal fistulas: summary statement. Inflamm Bowel Dis. 2015;21(4):723-30.

191. Schwartz DA, Ghazi LJ, Regueiro M. Guidelines for medical treatment of Crohn's perianal fistulas: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2015;21(4):737-52.

192. Molendijk I, Peeters KC, Baeten CI, Veenendaal RA, van der Meulen-de Jong AE. Improving the outcome of fistulising Crohn's disease. Best practice & research Clinical gastroenterology. 2014;28(3):505-18.

193. Keighley MR, Allan RN. Current status and influence of operation on perianal Crohn's disease. Int J Colorectal Dis. 1986;1(2):104-7.

194. Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut. 1980;21(6):525-7.

195. Schwartz DA, Loftus EV, Jr., Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002;122(4):875-80.

196. Tang LY, Rawsthorne P, Bernstein CN. Are perineal and luminal fistulas associated in Crohn's disease? A population-based study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2006;4(9):1130-4.

197. Haggett PJ, Moore NR, Shearman JD, Travis SP, Jewell DP, Mortensen NJ. Pelvic and perineal complications of Crohn's disease: assessment using magnetic resonance imaging. Gut. 1995;36(3):407-10.

198. Orsoni P, Barthet M, Portier F, Panuel M, Desjeux A, Grimaud JC. Prospective comparison of endosonography, magnetic resonance imaging and surgical findings in anorectal fistula and abscess complicating Crohn's disease. The British journal of surgery. 1999;86(3):360-4.

199. van Bodegraven AA, Sloots CE, Felt-Bersma RJ, Meuwissen SG. Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum. 2002;45(1):39-45; discussion -6.

200. Sloots CE, Felt-Bersma RJ, Poen AC, Cuesta MA, Meuwissen SG. Assessment and classification of fistula-in-ano in patients with Crohn's disease by hydrogen peroxide enhanced transanal ultrasound. Int J Colorectal Dis. 2001;16(5):292-7.

201. Buchanan GN, Halligan S, Bartram CI, Williams AB, Tarroni D, Cohen CR. Clinical examination, endosonography, and MR imaging in preoperative assessment of fistula in ano: comparison with outcome-based reference standard. Radiology. 2004;233(3):674-81.

202. Halligan S, Stoker J. Imaging of fistula in ano. Radiology. 2006;239(1):18-33.

203. Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. The British journal of surgery. 1976;63(1):1-12.

204. Bell SJ, Williams AB, Wiesel P, Wilkinson K, Cohen RC, Kamm MA. The clinical course of fistulating Crohn's disease. Alimentary pharmacology & therapeutics. 2003;17(9):1145-51.

205. van Koperen PJ, Safiruddin F, Bemelman WA, Slors JF. Outcome of surgical treatment for fistula in ano in Crohn's disease. The British journal of surgery. 2009;96(6):675-9.

206. Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology. 1980;79(2):357-65.

207. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology. 1982;83(2):383-7.

208. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. The American journal of gastroenterology. 1984;79(7):533-40.

209. Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009;15(1):17-24.

210. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. The American journal of gastroenterology. 2011;106(4):661-73.

211. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123(2):132-42.

212. Korelitz BI, Adler DJ, Mendelsohn RA, Sacknoff AL. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. The American journal of gastroenterology. 1993;88(8):1198-205.

213. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. The New England journal of medicine. 1999;340(18):1398-405.

214. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. The New England journal of medicine. 2004;350(9):876-85.

215. Sands BE, Blank MA, Patel K, van Deventer SJ, Study AI. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2004;2(10):912-20.

216. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005;128(4):862-9.

217. Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. The American journal of gastroenterology. 2000;95(12):3490-7.

218. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. The American journal of gastroenterology. 2001;96(3):722-9.

219. Bouguen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF, et al. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2013;11(8):975-81 e1-4.

220. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323-33; quiz 591.

221. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829-38.

222. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132(1):52-65.

223. Colombel JF, Schwartz DA, Sandborn WJ, Kamm MA, D'Haens G, Rutgeerts P, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009;58(7):940-8.

224. Hinojosa J, Gomollon F, Garcia S, Bastida G, Cabriada JL, Saro C, et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Alimentary pharmacology & therapeutics. 2007;25(4):409-18.

225. Panaccione R, Loftus EV, Jr., Binion D, McHugh K, Alam S, Chen N, et al. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Canadian journal of gastroenterology = Journal canadien de gastroenterologie. 2011;25(8):419-25.

226. Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Alimentary pharmacology & therapeutics. 2010;32(10):1228-39.

227. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. The New England journal of medicine. 2007;357(3):239-50.

228. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn's disease. The New England journal of medicine. 2007;357(3):228-38.

229. West RL, van der Woude CJ, Hansen BE, Felt-Bersma RJ, van Tilburg AJ, Drapers JA, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. Alimentary pharmacology & therapeutics. 2004;20(11-12):1329-36.

230. Dewint P, Hansen BE, Verhey E, Oldenburg B, Hommes DW, Pierik M, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63(2):292-9.

231. Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. The American journal of gastroenterology. 1998;93(3):442-8.

232. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. The American journal of gastroenterology. 1997;92(5):876-9.

233. Fellermann K, Ludwig D, Stahl M, David-Walek T, Stange EF. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). The American journal of gastroenterology. 1998;93(10):1860-6.

234. Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis. 1999;5(4):239-45.

235. Ierardi E, Principi M, Rendina M, Francavilla R, Ingrosso M, Pisani A, et al. Oral tacrolimus (FK 506) in Crohn's disease complicated by fistulae of the perineum. J Clin Gastroenterol. 2000;30(2):200-2.

236. Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003;125(2):380-8.

237. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB, American Gastroenterological Association Clinical Practice C. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003;125(5):1508-30.

238. de la Portilla F, Alba F, Garcia-Olmo D, Herrerias JM, Gonzalez FX, Galindo A. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis. 2013;28(3):313-23.

239. Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R, Avanzini MA, Ubezio C, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut. 2011;60(6):788-98.

240. Fichera A, Zoccali M. Guidelines for the surgical treatment of Crohn's perianal fistulas. Inflamm Bowel Dis. 2015;21(4):753-8.

241. Poggioli G, Laureti S, Pierangeli F, Rizzello F, Ugolini F, Gionchetti P, et al. Local injection of Infliximab for the treatment of perianal Crohn's disease. Dis Colon Rectum. 2005;48(4):768-74.

242. Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Scand J Gastroenterol. 2006;41(9):1064-72.

243. Poggioli G, Laureti S, Pierangeli F, Bazzi P, Coscia M, Gentilini L, et al. Local injection of adalimumab for perianal Crohn's disease: better than infliximab? Inflamm Bowel Dis. 2010;16(10):1631.

244. Tonelli F, Giudici F, Asteria CR. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study. Dis Colon Rectum. 2012;55(8):870-5.

245. Gaertner WB, Decanini A, Mellgren A, Lowry AC, Goldberg SM, Madoff RD, et al. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? Dis Colon Rectum. 2007;50(11):1754-60.

246. Hyder SA, Travis SP, Jewell DP, Mc CMNJ, George BD. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum. 2006;49(12):1837-41.

247. Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum. 2003;46(5):577-83.

248. van der Hagen SJ, Baeten CG, Soeters PB, Russel MG, Beets-Tan RG, van Gemert WG. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report. Dis Colon Rectum. 2005;48(4):758-67.

249. Yassin NA, Askari A, Warusavitarne J, Faiz OD, Athanasiou T, Phillips RK, et al. Systematic review: the combined surgical and medical treatment of fistulising perianal Crohn's disease. Alimentary pharmacology & therapeutics. 2014;40(7):741-9.

250. Molendijk I, Nuij VJ, van der Meulen-de Jong AE, van der Woude CJ. Disappointing durable remission rates in complex Crohn's disease fistula. Inflamm Bowel Dis. 2014;20(11):2022-8.

251. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232-9.

252. Lofberg R, Louis EV, Reinisch W, Robinson AM, Kron M, Camez A, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis. 2012;18(1):1-9.

253. Rozpondek P, Zwolinska-Wcislo M, Przybylska M, Mach T. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease]. Przeglad lekarski. 2011;68(9):602-5.

254. Gomez-Senent S, Barreiro-de-Acosta M, Garcia-Sanchez V. Enterocutaneous fistulas and Crohn s disease: clinical characteristics and response to treatment. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 2013;105(1):3-6.

255. de la Poza G, Lopez-Sanroman A, Taxonera C, Marin-Jimenez I, Gisbert JP, Bermejo F, et al. Genital fistulas in female Crohn's disease patients.: clinical characteristics and response to therapy. Journal of Crohn's & colitis. 2012;6(3):276-80.

256. Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. Journal of Crohn's & colitis. 2016;10(3):239-54.

257. Lakatos L, Pandur T, David G, Balogh Z, Kuronya P, Tollas A, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World journal of gastroenterology : WJG. 2003;9(10):2300-7.

258. Barreiro-de Acosta M, Dominguez-Munoz JE, Nunez-Pardo de Vera MC, Lozano-Leon A, Lorenzo A, Pena S. Relationship between clinical features of Crohn's disease and the risk of developing extraintestinal manifestations. European journal of gastroenterology & hepatology. 2007;19(1):73-8.

259. Ott C, Scholmerich J. Extraintestinal manifestations and complications in IBD. Nature reviews Gastroenterology & hepatology. 2013;10(10):585-95.

260. Jose FA, Garnett EA, Vittinghoff E, Ferry GD, Winter HS, Baldassano RN, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(1):63-8.

261. Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106(1):110-9.

262. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42(3):387-91.

263. de Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. The Journal of rheumatology. 2000;27(12):2860-5.

264. Orchard TR, Holt H, Bradbury L, Hammersma J, McNally E, Jewell DP, et al. The prevalence, clinical features and association of HLA-B27 in sacroiliitis associated with established Crohn's disease. Alimentary pharmacology & therapeutics. 2009;29(2):193-7.

265. Salvarani C, Vlachonikolis IG, van der Heijde DM, Fornaciari G, Macchioni P, Beltrami M, et al. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol. 2001;36(12):1307-13.

266. Queiro R, Maiz O, Intxausti J, de Dios JR, Belzunegui J, Gonzalez C, et al. Subclinical sacroiliitis in inflammatory bowel disease: a clinical and follow-up study. Clinical rheumatology. 2000;19(6):445-9.

267. Peeters H, Vander Cruyssen B, Mielants H, de Vlam K, Vermeire S, Louis E, et al. Clinical and genetic factors associated with sacroiliitis in Crohn's disease. J Gastroenterol Hepatol. 2008;23(1):132-7.

268. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and rheumatism. 1984;27(4):361-8.

269. Puhakka KB, Jurik AG, Schiottz-Christensen B, Hansen GV, Egund N, Christiansen JV, et al. MRI abnormalities of sacroiliac joints in early spondylarthropathy: a 1-year follow-up study. Scandinavian journal of rheumatology. 2004;33(5):332-8.

270. Braun J, Baraliakos X, Golder W, Hermann KG, Listing J, Brandt J, et al. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Annals of the rheumatic diseases. 2004;63(9):1046-55.

271. Ferraz MB, Tugwell P, Goldsmith CH, Atra E. Meta-analysis of sulfasalazine in ankylosing spondylitis. The Journal of rheumatology. 1990;17(11):1482-6.

272. Palm O, Moum B, Ongre A, Gran JT. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). The Journal of rheumatology. 2002;29(3):511-5.

273. Olivieri I, Cantini F, Castiglione F, Felice C, Gionchetti P, Orlando A, et al. Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmunity reviews. 2014;13(8):822-30.

274. Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet. 2000;356(9244):1821-2.

275. Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G, et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Annals of the rheumatic diseases. 2004;63(12):1664-9.

276. Herfarth H, Obermeier F, Andus T, Rogler G, Nikolaus S, Kuehbacher T, et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol. 2002;97(10):2688-90.

277. Peluso R, Manguso F, Vitiello M, Iervolino S, Di Minno MN. Management of arthropathy in inflammatory bowel diseases. Therapeutic advances in chronic disease. 2015;6(2):65-77.

278. Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacological research : the official journal of the Italian Pharmacological Society. 2002;46(1):1-6.

279. Evans JM, McMahon AD, Murray FE, McDevitt DG, MacDonald TM. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut. 1997;40(5):619-22.

280. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2000;95(8):1949-54.

281. Bonner GF, Fakhri A, Vennamaneni SR. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(6):751-7.

282. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006;101(2):311-7.

283. Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006;4(2):203-11.

284. Dougados M, vam der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis and rheumatism. 1995;38(5):618-27.

285. Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis and rheumatism. 1996;39(12):2004-12.

286. Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis and rheumatism. 2002;46(3):755-65.

287. Gionchetti P, Rizzello F. IBD: IBD and spondyloarthritis: joint management. Nature reviews Gastroenterology & hepatology. 2016;13(1):9-10.

288. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis and rheumatism. 2006;54(7):2136-46.

289. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359(9313):1187-93.

290. Gorman JD, Sack KE, Davis JC, Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. The New England journal of medicine. 2002;346(18):1349-56.

291. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis and rheumatism. 2005;52(2):582-91.

292. Lambert RG, Salonen D, Rahman P, Inman RD, Wong RL, Einstein SG, et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis and rheumatism. 2007;56(12):4005-14.

293. Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Annals of the rheumatic diseases. 2008;67(3):340-5.

294. Miheller P, Lorinczy K, Lakatos PL. Clinical relevance of changes in bone metabolism in inflammatory bowel disease. World journal of gastroenterology : WJG. 2010;16(44):5536-42.

295. Reinshagen M. Osteoporosis in inflammatory bowel disease. Journal of Crohn's & colitis. 2008;2(3):202-7.

296. Wahner H. Technical aspects and clinical interpretation of bone mineral measurements. Public health reports. 1989;104 Suppl:27-30.

297. Weber NK, Fidler JL, Keaveny TM, Clarke BL, Khosla S, Fletcher JG, et al. Validation of a CT-Derived Method for Osteoporosis Screening in IBD Patients Undergoing Contrast-Enhanced CT Enterography. Am J Gastroenterol. 2014.

298. Siffledeen JS, Siminoski K, Jen H, Fedorak RN. Vertebral fractures and role of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol. 2007;5(6):721-8.

299. Klaus J, Armbrecht G, Steinkamp M, Bruckel J, Rieber A, Adler G, et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut. 2002;51(5):654-8.

300. Stockbrugger RW, Schoon EJ, Bollani S, Mills PR, Israeli E, Landgraf L, et al. Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. Alimentary pharmacology & therapeutics. 2002;16(8):1519-27.

301. Black DM, Steinbuch M, Palermo L, Dargent-Molina P, Lindsay R, Hoseyni MS, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2001;12(7):519-28.

302. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA : the journal of the American Medical Association. 2005;293(18):2257-64.

303. Melek J, Sakuraba A. Efficacy and Safety of Medical Therapy for Low Bone Mineral Density in Patients With Inflammatory Bowel Disease: A Meta-analysis and Systematic Review. Clin Gastroenterol Hepatol. 2014;12(1):32-44 e5.

304. Soo I, Siffledeen J, Siminoski K, McQueen B, Fedorak RN. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial. Journal of Crohn's & colitis. 2012;6(7):777-86.

305. Reffitt DM, Meenan J, Sanderson JD, Jugdaohsingh R, Powell JJ, Thompson RP. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2003;15(12):1267-73.

306. Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol. 2007;102(3):662-7.

307. Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol. 2008;6(1):41-5.

308. Haapamaki J, Roine RP, Turunen U, Farkkila MA, Arkkila PE. Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. Journal of Crohn's & colitis. 2011;5(1):41-7.

309. Yarur AJ, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011;106(4):741-7.

310. Rungoe C, Basit S, Ranthe MF, Wohlfahrt J, Langholz E, Jess T. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut. 2013;62(5):689-94.

311. Kristensen SL, Ahlehoff O, Lindhardsen J, Erichsen R, Jensen GV, Torp-Pedersen C, et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death--a Danish nationwide cohort study. PloS one. 2013;8(2):e56944.

312. Osterman MT, Yang YX, Brensinger C, Forde KA, Lichtenstein GR, Lewis JD. No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease. Clin Gastroenterol Hepatol. 2011;9(10):875-80.

313. Douglas JG, McDonald CF, Leslie MJ, Gillon J, Crompton GK, McHardy GJ. Respiratory impairment in inflammatory bowel disease: does it vary with disease activity? Respiratory medicine. 1989;83(5):389-94.

314. Songur N, Songur Y, Tuzun M, Dogan I, Tuzun D, Ensari A, et al. Pulmonary function tests and high-resolution CT in the detection of pulmonary involvement in inflammatory bowel disease. Journal of clinical gastroenterology. 2003;37(4):292-8.

315. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005;129(3):827-36.

316. Weng X, Liu L, Barcellos LF, Allison JE, Herrinton LJ. Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern california-managed care organization. Am J Gastroenterol. 2007;102(7):1429-35.

317. Peyrin-Biroulet L, Loftus EV, Jr., Colombel JF, Sandborn WJ. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis. 2011;17(1):471-8.

318. Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108(2):240-8.

319. Eaton TE, Lambie N, Wells AU. Bronchiectasis following colectomy for Crohn's disease. Thorax. 1998;53(6):529-31.

320. Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology. 2013;145(3):521-36.

321. Vitellas KM, Enns RA, Keogan MT, Freed KS, Spritzer CE, Baillie J, et al. Comparison of MR cholangiopancreatographic techniques with contrast-enhanced cholangiography in the evaluation of sclerosing cholangitis. AJR Am J Roentgenol. 2002;178(2):327-34.

322. Talwalkar JA, Angulo P, Johnson CD, Petersen BT, Lindor KD. Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology. 2004;40(1):39-45.

323. Cullen SN, Chapman RW. The medical management of primary sclerosing cholangitis. Seminars in liver disease. 2006;26(1):52-61.

324. Braden B, Halliday J, Aryasingha S, Sharifi Y, Checchin D, Warren BF, et al. Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2012;10(3):303-8.

325. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. The New England journal of medicine. 1997;336(10):691-5.

326. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology. 2001;121(4):900-7.

327. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50(3):808-14.

328. Sjoqvist U, Tribukait B, Ost A, Einarsson C, Oxelmark L, Lofberg R. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Anticancer research. 2004;24(5B):3121-7.

329. Lindstrom L, Boberg KM, Wikman O, Friis-Liby I, Hultcrantz R, Prytz H, et al. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Alimentary pharmacology & therapeutics. 2012;35(4):451-7.

330. Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol. 2011;106(9):1638-45.

331. Singh S, Khanna S, Pardi DS, Loftus EV, Jr., Talwalkar JA. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2013;19(8):1631-8.

332. Baluyut AR, Sherman S, Lehman GA, Hoen H, Chalasani N. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc. 2001;53(3):308-12.

333. Gotthardt DN, Rudolph G, Kloters-Plachky P, Kulaksiz H, Stiehl A. Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment. Gastrointest Endosc. 2010;71(3):527-34.

334. Lindor KD, Kowdley KV, Harrison ME. ACG Clinical Guideline: Primary Sclerosing Cholangitis. The American journal of gastroenterology. 2015;110(5):646-59.

335. Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgraduate medical journal. 2005;81(959):580-5.

336. Requena L, Sanchez Yus E. Erythema nodosum. Seminars in cutaneous medicine and surgery. 2007;26(2):114-25.

337. Nguyen GC, Torres EA, Regueiro M, Bromfield G, Bitton A, Stempak J, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006;101(5):1012-23.

338. Emanuel PO, Phelps RG. Metastatic Crohn's disease: a histopathologic study of 12 cases. Journal of cutaneous pathology. 2008;35(5):457-61.

339. Orchard TR, Chua CN, Ahmad T, Cheng H, Welsh KI, Jewell DP. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology. 2002;123(3):714-8.

340. Clayton TH, Walker BP, Stables GI. Treatment of chronic erythema nodosum with infliximab. Clinical and experimental dermatology. 2006;31(6):823-4.

341. Andrisani G, Guidi L, Papa A, Armuzzi A. Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. European review for medical and pharmacological sciences. 2012;16(7):890-901.

342. Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheumatic diseases clinics of North America. 2007;33(4):787-802, vi.

343. Freeman HJ. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease. Can J Gastroenterol. 2005;19(10):603-6.

344. Menachem Y, Gotsman I. Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease. The Israel Medical Association journal : IMAJ. 2004;6(2):88-90.

345. Polcz M, Gu J, Florin T. Pyoderma gangrenosum in inflammatory bowel disease: the experience at Mater Health Services' Adult Hospital 1998-2009. Journal of Crohn's & colitis. 2011;5(2):148-51.

346. Weenig RH, Davis MD, Dahl PR, Su WP. Skin ulcers misdiagnosed as pyoderma gangrenosum. The New England journal of medicine. 2002;347(18):1412-8.

347. Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. Journal of the European Academy of Dermatology and Venereology : JEADV. 2009;23(9):1008-17.

348. Lakatos PL, Lakatos L, Kiss LS, Peyrin-Biroulet L, Schoepfer A, Vavricka S. Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion. 2012;86 Suppl 1:28-35.

349. Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ. 2006;333(7560):181-4.

350. Juillerat P, Mottet C, Pittet V, Froehlich F, Felley C, Gonvers JJ, et al. Extraintestinal manifestations of Crohn's disease. Digestion. 2007;76(2):141-8.

351. Matis WL, Ellis CN, Griffiths CE, Lazarus GS. Treatment of pyoderma gangrenosum with cyclosporine. Archives of dermatology. 1992;128(8):1060-4.

352. Ljung T, Staun M, Grove O, Fausa O, Vatn MH, Hellstrom PM. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol. 2002;37(9):1108-10.

353. Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98(8):1821-6.

354. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505-9.

355. Zold E, Nagy A, Devenyi K, Zeher M, Barta Z. Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: Two birds with one stone. World journal of gastroenterology : WJG. 2009;15(18):2293-5.

356. Alkhouri N, Hupertz V, Mahajan L. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease. Inflamm Bowel Dis. 2009;15(6):803-6.

357. Carinanos I, Acosta MB, Domenech E. Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(12):E153-4.

358. Agarwal A, Andrews JM. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Alimentary pharmacology & therapeutics. 2013;38(6):563-72.

359. Poritz LS, Lebo MA, Bobb AD, Ardell CM, Koltun WA. Management of peristomal pyoderma gangrenosum. Journal of the American College of Surgeons. 2008;206(2):311-5.

360. Cohen PR. Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet journal of rare diseases. 2007;2:34.

361. Travis S, Innes N, Davies MG, Daneshmend T, Hughes S. Sweet's syndrome: an unusual cutaneous feature of Crohn's disease or ulcerative colitis. The South West Gastroenterology Group. Eur J Gastroenterol Hepatol. 1997;9(7):715-20.

362. Ytting H, Vind I, Bang D, Munkholm P. Sweet's syndrome--an extraintestinal manifestation in inflammatory bowel disease. Digestion. 2005;72(2-3):195-200.

363. Marzano AV, Ishak RS, Saibeni S, Crosti C, Meroni PL, Cugno M. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria. Clinical reviews in allergy & immunology. 2013;45(2):202-10.

364. Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol. 2011;106(4):713-8.

365. Fumery M, Xiaocang C, Dauchet L, Gower-Rousseau C, Peyrin-Biroulet L, Colombel JF. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. Journal of Crohn's & colitis. 2014;8(6):469-79.

366. Pleet JL, Vaughn BP, Morris JA, Moss AC, Cheifetz AS. The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis. Alimentary pharmacology & therapeutics. 2014;39(9):940-8.

367. Yuhara H, Steinmaus C, Corley D, Koike J, Igarashi M, Suzuki T, et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics. 2013;37(10):953-62.

368. Scoville EA, Konijeti GG, Nguyen DD, Sauk J, Yajnik V, Ananthakrishnan AN. Venous thromboembolism in patients with inflammatory bowel diseases: a case-control study of risk factors. Inflamm Bowel Dis. 2014;20(4):631-6.

369. Isene R, Bernklev T, Hoie O, Langholz E, Tsianos E, Stockbrugger R, et al. Thromboembolism in inflammatory bowel disease: results from a prospective, population-based European inception cohort. Scand J Gastroenterol. 2014;49(7):820-5.

370. Nguyen GC, Boudreau H, Harris ML, Maxwell CV. Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol. 2009;7(3):329-34.

371. Lazzerini M, Bramuzzo M, Maschio M, Martelossi S, Ventura A. Thromboembolism in pediatric inflammatory bowel disease: systematic review. Inflamm Bowel Dis. 2011;17(10):2174-83.

372. Kappelman MD, Horvath-Puho E, Sandler RS, Rubin DT, Ullman TA, Pedersen L, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011;60(7):937-43.

373. Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol. 2007;102(1):174-86.

374. Higgins PD, Skup M, Mulani PM, Lin J, Chao J. Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2015;13(2):316-21.

375. Bollen L, Vande Casteele N, Peeters M, Bessonov K, Van Steen K, Rutgeerts P, et al. Short-term effect of infliximab is reflected in the clot lysis profile of patients with inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2015;21(3):570-8.

376. Papay P, Miehsler W, Tilg H, Petritsch W, Reinisch W, Mayer A, et al. Clinical presentation of venous thromboembolism in inflammatory bowel disease. Journal of Crohn's & colitis. 2013;7(9):723-9.

377. Chong LY, Fenu E, Stansby G, Hodgkinson S, Guideline Development G. Management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE guidance. BMJ. 2012;344:e3979.

378. Qaseem A, Snow V, Barry P, Hornbake ER, Rodnick JE, Tobolic T, et al. Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Annals of family medicine. 2007;5(1):57-62.

379. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S-94S.

380. Nguyen GC, Bernstein CN, Bitton A, Chan AK, Griffiths AM, Leontiadis GI, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014;146(3):835-48 e6.

381. Nguyen GC, Bernstein CN. Duration of anticoagulation for the management of venous thromboembolism in inflammatory bowel disease: a decision analysis. Am J Gastroenterol. 2013;108(9):1486-95.

382. Ra G, Thanabalan R, Ratneswaran S, Nguyen GC. Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients. Journal of Crohn's & colitis. 2013;7(10):e479-85.

383. Baser O, Liu X, Phatak H, Wang L, Mardekian J, Kawabata H, et al. Venous thromboembolism prophylaxis and clinical consequences in medically ill patients. American journal of therapeutics. 2013;20(2):132-42.

384. Chande N. Prevention of venous thromboembolism in hospitalized patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(3):669-71.

385. Tinsley A, Naymagon S, Trindade AJ, Sachar DB, Sands BE, Ullman TA. A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. Journal of clinical gastroenterology. 2013;47(1):e1-6.

386. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e326S-50S.